Avadel Pharmaceuticals-adr (AVDL)

$16.2

+0.26

(+1.63%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $15.92
    $16.33
    $16.20
    downward going graph

    1.73%

    Downside

    Day's Volatility :2.51%

    Upside

    0.8%

    downward going graph
  • $13.42
    $19.09
    $16.20
    downward going graph

    17.16%

    Downside

    52 Weeks Volatility :29.7%

    Upside

    15.14%

    downward going graph

Returns

PeriodAvadel Pharmaceuticals-adrSector (Health Care)Index (Russel 2000)
3 Months
-6.36%
6.4%
0.0%
6 Months
8.72%
6.0%
0.0%
1 Year
16.8%
8.5%
0.0%
3 Years
122.22%
14.6%
-20.8%

Highlights

Market Capitalization
1.6B
Book Value
$0.82
Earnings Per Share (EPS)
-1.82
PEG Ratio
0.07
Wall Street Target Price
23.65
Profit Margin
-284.42%
Operating Margin TTM
-95.79%
Return On Assets TTM
-54.91%
Return On Equity TTM
-779.92%
Revenue TTM
55.1M
Revenue Per Share TTM
0.63
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
16.6M
EBITDA
-133.9M
Diluted Eps TTM
-1.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
0.75
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Avadel Pharmaceuticals-adr(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 45.99%

Current $16.20
Target $23.65

Technicals Summary

Sell

Neutral

Buy

Avadel Pharmaceuticals-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avadel Pharmaceuticals-adr
Avadel Pharmaceuticals-adr
7.93%
8.72%
16.8%
122.22%
131.1%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.26%
4.21%
47.47%
49.15%
67.79%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.97%
5.95%
0.22%
20.24%
20.24%
Zoetis Inc.
Zoetis Inc.
4.38%
-6.6%
-2.69%
-9.83%
54.03%
Viatris Inc.
Viatris Inc.
13.09%
1.72%
12.98%
-15.79%
-27.54%
Catalent, Inc.
Catalent, Inc.
2.5%
16.24%
21.69%
-49.0%
5.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avadel Pharmaceuticals-adr
Avadel Pharmaceuticals-adr
NA
NA
0.07
-0.5
-7.8
-0.55
NA
0.82
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.17
39.17
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.47
34.47
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avadel Pharmaceuticals-adr
Avadel Pharmaceuticals-adr
Buy
$1.6B
131.1%
NA
-284.42%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.5B
67.79%
39.17
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.24%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.8B
54.03%
34.47
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-27.54%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
5.41%
211.02
-28.44%

Insights on Avadel Pharmaceuticals-adr

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 47.5% return, outperforming this stock by 30.7%

Institutional Holdings

  • HHG PLC

    11.57%
  • RTW INVESTMENTS, LLC

    7.23%
  • Polar Capital Holdings PLC

    7.02%
  • Gendell Jeffrey L

    5.84%
  • Vivo Capital, LLC

    4.26%
  • WEALTH EFFECTS LLC

    2.51%

Company Information

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.

Organization
Avadel Pharmaceuticals-adr
Employees
154
CEO
Mr. Gregory J. Divis Jr.
Industry
Health Technology

FAQs